Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Lerociclib Plus Endocrine Therapy in Advanced HR+/HER2- Metastatic Breast Cancer
2021-005238-40Phase 2Completed
- Sponsor
- EQRx
- Start
- Mar 2022
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of lerociclib in breast cancer, sponsored by EQRx. Primary endpoint: Incidence of adverse events (AEs) and serious adverse events (SAEs). Started Mar 2022; status: completed.
02
Drugs
lerociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2021-005238-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005238-40.